These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 8345202)

  • 1. Recombinant tetravalent group A streptococcal M protein vaccine.
    Dale JB; Chiang EY; Lederer JW
    J Immunol; 1993 Aug; 151(4):2188-94. PubMed ID: 8345202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses.
    Bronze MS; Courtney HS; Dale JB
    J Immunol; 1992 Feb; 148(3):888-93. PubMed ID: 1370521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes.
    Bessen D; Fischetti VA
    J Immunol; 1990 Aug; 145(4):1251-6. PubMed ID: 1696296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence and type-specific immunogenicity of the amino-terminal region of type 1 streptococcal M protein.
    Kraus W; Haanes-Fritz E; Cleary PP; Seyer JM; Dale JB; Beachey EH
    J Immunol; 1987 Nov; 139(9):3084-90. PubMed ID: 2444650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain.
    Bronze MS; Dale JB
    J Immunol; 1993 Sep; 151(5):2820-8. PubMed ID: 7689617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
    McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
    Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
    Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
    BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
    Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
    Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping a conserved conformational epitope from the M protein of group A streptococci.
    Relf WA; Cooper J; Brandt ER; Hayman WA; Anders RF; Pruksakorn S; Currie B; Saul A; Good MF
    Pept Res; 1996; 9(1):12-20. PubMed ID: 8727479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitopes of group A streptococcal M protein shared with antigens of articular cartilage and synovium.
    Baird RW; Bronze MS; Kraus W; Hill HR; Veasey LG; Dale JB
    J Immunol; 1991 May; 146(9):3132-7. PubMed ID: 2016540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic peptide fragments of streptococcal M proteins.
    Seyer JM; Dale JB; Beachey EH
    Dev Biol Stand; 1986; 63():101-8. PubMed ID: 2427375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective and nonprotective epitopes of chemically synthesized peptides of the NH2-terminal region of type 6 streptococcal M protein.
    Beachey EH; Seyer JM
    J Immunol; 1986 Mar; 136(6):2287-92. PubMed ID: 2419429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
    Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
    Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence of protective epitopes of streptococcal M proteins shared with cardiac sarcolemmal membranes.
    Sargent SJ; Beachey EH; Corbett CE; Dale JB
    J Immunol; 1987 Aug; 139(4):1285-90. PubMed ID: 2440952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments.
    Dale JB
    Vaccine; 1999 Jan; 17(2):193-200. PubMed ID: 9987154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface-exposed conserved region of the streptococcal M protein induces antibodies cross-reactive with denatured forms of myosin.
    Vashishtha A; Fischetti VA
    J Immunol; 1993 May; 150(10):4693-701. PubMed ID: 8482854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies.
    Pruksakorn S; Galbraith A; Houghten RA; Good MF
    J Immunol; 1992 Oct; 149(8):2729-35. PubMed ID: 1383324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non-opsonic epitopes.
    Sandin C; Carlsson F; Lindahl G
    Mol Microbiol; 2006 Jan; 59(1):20-30. PubMed ID: 16359315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant, octavalent group A streptococcal M protein vaccine.
    Dale JB; Simmons M; Chiang EC; Chiang EY
    Vaccine; 1996 Jul; 14(10):944-8. PubMed ID: 8873386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of a 26-valent group A streptococcal vaccine.
    Hu MC; Walls MA; Stroop SD; Reddish MA; Beall B; Dale JB
    Infect Immun; 2002 Apr; 70(4):2171-7. PubMed ID: 11895984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.